Journal of Controlled Release最新文献

{"title":"Content list including Graphcal Abstracts","authors":"","doi":"10.1016/S0168-3659(25)00316-5","DOIUrl":"10.1016/S0168-3659(25)00316-5","url":null,"abstract":"","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"381 ","pages":"Article 113696"},"PeriodicalIF":10.5,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143815401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Overcoming P-glycoprotein-mediated multidrug resistance in cancer cells through micelle-forming PHPMA-b-PPO diblock copolymers for doxorubicin delivery” [Journal of Controlled Release 381 (2025) 113645]","authors":"Martin Kaňa , Alena Braunová , Daniil Starenko , Markéta Frejková , Jan Bouček , Blanka Říhová , Marek Kovář , Tomáš Etrych , Milada Šírová","doi":"10.1016/j.jconrel.2025.113685","DOIUrl":"10.1016/j.jconrel.2025.113685","url":null,"abstract":"","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"382 ","pages":"Article 113685"},"PeriodicalIF":10.5,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143806984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current strategies for senescence treatment: Focused on theranostic performance of nanomaterials","authors":"Yiyang Cong,&nbsp;Xiaoyang Li,&nbsp;Hao Hong","doi":"10.1016/j.jconrel.2025.113710","DOIUrl":"10.1016/j.jconrel.2025.113710","url":null,"abstract":"<div><div>Age-related diseases imposed heavy burdens to the healthcare systems globally, while cell senescence served as one fundamental molecular/cellular basis for these diseases. How to tackle the senescence-relevant problems is a hotspot for biomedical research. In this review article, the hallmarks and molecular pathways of cell senescence were firstly discussed, followed by the introduction of the current anti-senescence strategies, including senolytics and senomorphics. With suitable physical or chemical properties, multiple types of nanomaterials were used successfully in senescence therapeutics, as well as senescence detection. Based on the accumulating knowledges for senescence, the rules of how to use these nanoplatforms more efficiently against senescence were also summarized, including but not limited to surface modification, material-cargo interactions, factor responsiveness etc. The comparison of these “senescence-selective” nanoplatforms to other treatment options (prodrugs, ADCs, PROTACs, CART etc.) was also given. Learning from the past, nanotechnology can add more choice for treating age-related diseases, and provide more (diagnostic) information to further our understanding of senescence process.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"382 ","pages":"Article 113710"},"PeriodicalIF":10.5,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143814045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Harnessing innovation in microneedle technology for Women's healthcare","authors":"Yu Ting He, Xin Yao Geng, Ming Yu Chang, Fei Fei Li, Xin Ling Du, Bo Zhi Chen, Xin Dong Guo","doi":"10.1016/j.jconrel.2025.113706","DOIUrl":"https://doi.org/10.1016/j.jconrel.2025.113706","url":null,"abstract":"Women's health management plays a crucial role in modern healthcare, encompassing the prevention, detection, and treatment of female diseases. However, existing technologies often face challenges, such as the invasiveness and discomfort associated with serological testing and injection-based therapies. Microneedles, as an emerging technology in biomedical engineering, demonstrate significant advantages. These micron-sized transdermal devices are applicable in a range of applications, from drug delivery to interstitial fluid sampling, and their painless, minimally invasive nature significantly enhances medication compliance. In recent years, microneedles have been widely utilized in women's health management, showing promising results in early disease prevention and subsequent treatment. Although there are reviews about microneedles applied in disease treatment management, few of them focus on the application of microneedles in the prevention and early detection of women's disease. Herein, we present a comprehensive overview of the current application status of microneedles in women's health management, with a special emphasis on their design and mechanism for disease prevention, and treatment in women. Finally, we discuss the advantages and limitations of microneedles in women's health management, and propose suggestions for future research direction.","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"38 1","pages":""},"PeriodicalIF":10.8,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143819410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sinomenine-glycyrrhizic acid self-assembly enhanced the anti-inflammatory effect of sinomenine in the treatment of rheumatoid arthritis","authors":"Haixu Jiang, Qingyi Lu, Xuemei Huang, Honglin Zhang, Jia Zeng, Mengdan Wang, Jie Xu, Zhihua Yuan, Qiuzhu Wei, Enfan Xiao, Penglong Wang, Guangrui Huang, Anlong Xu","doi":"10.1016/j.jconrel.2025.113718","DOIUrl":"https://doi.org/10.1016/j.jconrel.2025.113718","url":null,"abstract":"Rheumatoid arthritis (RA) is a common chronic systemic autoimmune disease that causes cartilage and bone damage in multiple joints, ultimately leading to disability. There is an urgent need to develop multidimensional strategies to treat RA. Sinomenine (SIN) has the distinctive pharmacological activity in treating RA, but its broader clinical application is limited by its exceedingly short half-life and adverse digestive tract effects. To overcome this obstacle, a self-assembled nanohydrogel (S-G hydrogel) was designed and produced with sinomenine (SIN) and glycyrrhizic acid (GA) without carriers or catalysts through noncovalent bonding. The S-G hydrogel could promote the absorption of SIN probably by protecting SIN from releasing and degrading in the acid circumstances. Oral intake of the S-G hydrogel significantly suppressed the overactivation of neutrophil <em>via</em> the NF-κB and MAPK pathways in mice with RA. Furthermore, the S-G hydrogel regulated neutrophil activity by reversing apoptosis delay and decreasing autophagy-dependent NET formation. In summary, this study presents a self-assembled hydrogel with promising potential for clinical application, and offers a novel strategy to develop new drugs from the existing patent medicine composed of compounds from traditional Chinese medicine, as well as a special insight to elucidate the herb-matching mechanism in decoction prescriptions.","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"49 1","pages":""},"PeriodicalIF":10.8,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143819409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"STING-activable immunomodulatory bio-glue for multiple postsurgical management","authors":"Mengzi Hu ,&nbsp;Yaqiong Wang ,&nbsp;Xue-Bo Yin","doi":"10.1016/j.jconrel.2025.113714","DOIUrl":"10.1016/j.jconrel.2025.113714","url":null,"abstract":"<div><div>In addition to the robust adhesive properties, there is a pressing demand for ideal adhesives in tumor surgery that possess anti-tumor therapeutic effects. In this study, we introduce BSA-MnO₂-GP@Ca-Y (BMGY) bio-glue by integrating bovine serum albumin (BSA)-MnO₂, genipin (GP), and Ca-Y zeolite. Ca-Y zeolite exhibits the thrombin activity for hemostasis, while the cross-linking of BSA, GP, and skin tissue induces wound adherence upon laser irradiation for normalized skin structure within nine days. The heat generated during the “photothermal suture” process ablates residual tumor cells and produces antigen fragments, which are internalized by antigen presenting cells. The released Mn ions subsequently activate the cGAS-STING pathway, enhancing immunogenicity. Consequently, tumor-infiltrating p-TBK1 and interferon-β levels are significantly increased, ensuring robust anti-tumor immunity following BMGY treatment. Thus, BMGY bio-glue achieves hemostasis, wound bonding, ablation of residual tumor cells, and tumor recurrence inhibition, simultaneously. Beyond Ca-Y zeolite, BSA-MnO₂-GP serves as a versatile platform for loading other drugs or active species to boost therapeutic efficacy. Therefore, we present a successful bio-glue paradigm with significant translational potential for various postsurgical management applications.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"382 ","pages":"Article 113714"},"PeriodicalIF":10.5,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143797908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A dual-action strategy: Wound microenvironment responsive hydrogel and exosome-mediated glucose regulation enhance inside-out diabetic wound repair","authors":"Shaoxin Tang ,&nbsp;Keru Feng ,&nbsp;Rui Yang ,&nbsp;Yang Cheng ,&nbsp;Nianyuan Shi ,&nbsp;Hui Zhang ,&nbsp;Zhao Wei ,&nbsp;Yufei Ma","doi":"10.1016/j.jconrel.2025.113716","DOIUrl":"10.1016/j.jconrel.2025.113716","url":null,"abstract":"<div><div>Sustained hyperglycemia induces complex pathological microenvironment in diabetic wounds, significantly hindering wound healing. Most current therapeutic approaches (e.g., hydrogel dressings) have paid little attention to the effect of blood glucose levels on diabetic wound healing. In this study, a synergetic therapeutic strategy including a wound microenvironment responsive, multifunctional hydrogel and the exosome-mediated glucose regulation is developed for diabetic wound treatment. First, a gelatin-dopamine (Gel<img>DA) crosslinked hyaluronic acid-phenylboronic acid (HA-PBA) hydrogel (GDHP) is constructed with good injectable, self-healing, and adhesive abilities. Such GDHP hydrogel not only can effectively relieve oxidative stress and reduce inflammation, but also promote keratinocyte migration. Then, ciprofloxacin hydrochloride (CIP·H) is loaded to prepare the GDHPC hydrogel that may respond to diabetic wound microenvironment (e.g., low pH, high glucose and reactive oxygen species) and degrade for controlled release of CIP·H, showing on-demand antibacterial properties. Exosomes derived from human umbilical cord mesenchymal stem cells (hucMSC-exos) are administered via tail vein injection in diabetic mice, which may repair injured pancreatic islets by modulating the pancreatic immune microenvironment, thus promoting insulin secretion and further reducing blood glucose levels. By applying this synergetic therapeutic strategy, the full-thickness cutaneous wounds in type 1 diabetic mice heal well and quickly compared to that treated with the GDHPC hydrogel and the hucMSC-exos alone. This promotion effect on wound healing may associate with reducing inflammation and promoting angiogenesis. This study sheds new light on the development of a dual-action strategy that can effectively maintain glucose homeostasis, improve the wound microenvironment, and consequently promote inside-out repair of diabetic wounds, offering a promising therapeutic avenue for future diabetic wound treatment.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"382 ","pages":"Article 113716"},"PeriodicalIF":10.5,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143798293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing continuous micromixing and extrusion downsizing for PEGylated nanoliposomes remotely loaded with doxorubicin or the steroid pro-drug methylprednisolone hemisuccinate","authors":"Keren Turjeman ,&nbsp;Alexander-Nicholas Egler-Kemmerer ,&nbsp;Dima Shamrakov ,&nbsp;Christine Paulus ,&nbsp;Raphael Thiermann ,&nbsp;Yechezkel Barenholz ,&nbsp;Regina Bleul","doi":"10.1016/j.jconrel.2025.113707","DOIUrl":"10.1016/j.jconrel.2025.113707","url":null,"abstract":"<div><div>Since the FDA approval of the first nanodrug Doxil® in 1995, twenty subsequent liposome and lipid nanoparticle (LNP) based drugs (of which 10 are nanodrugs), were approved by the FDA. The application of such drug-products was considerably boosted by the mRNA-LNP based vaccines used to stop the COVID-19 pandemic. Research on lipid-based vesicles and nanoparticles for drug delivery dates to the 1970s and has culminated in both continuous flow and extrusion-based fabrication processes for current state-of-the-art GMP industrial production of nanoliposomes and lipid nanoparticles. In this study, we compare these two approaches for the preparation of two PEGylated nanoliposome-based drug-products, keeping all other production steps leading to the final drug-product identical. One of these products, generic Doxil®, is remotely and actively loaded with the anthracycline doxorubicin (an amphipathic weak base) driven by a transmembrane ammonium gradient, while the other is methylprednisolone hemisuccinate (an amphipathic weak acid) remotely and actively loaded via a transmembrane acetate gradient. We demonstrate that a microfluidics-based micromixer approach yields equivalent or even better drug-products, especially since the downsizing by microfluidics is not performed above the temperature range of lipid phase transition. The main difference in the physico-chemical features is that size distribution of the microfluidics prepared PEGylated nano liposomes was significantly narrower and morphological analysis by cryo-TEM confirmed higher homogeneity. An additional advantage of the microfluidic approach is that it is a continuous production. Therefore, it enables the direct production of large volumes of high-quality nano-liposomal based drug-products.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"382 ","pages":"Article 113707"},"PeriodicalIF":10.5,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143797865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"It's not right, it's not even wrong","authors":"Michael V. Sefton","doi":"10.1016/j.jconrel.2025.113715","DOIUrl":"10.1016/j.jconrel.2025.113715","url":null,"abstract":"<div><div>Standard advice for new university graduates is to embrace failure. If you don't fail, you aren't pushing the boundaries. The title of this work, originally presented at a symposium at the 2024 World Biomaterials Congress in Daegu, South Korea. “Learning from Successful Failures in Tissue Engineering &amp; Regenerative Medicine”, is a quote from Wolfgang Pauli, upon hearing a scientific presentation that disappointed him because it didn't even point to a better answer – it wasn't even wrong.</div><div>Often our scientific contributions are incomplete or go only so far before they run up against unforeseen obstacles. We tried to immobilize heparin to a polyvinyl alcohol hydrogel to prepare a nonthrombogenic material but we didn't appreciate the consequences of non-adherent platelet contacts on material compatibility. We tried to microencapsulate mammalian cells and particularly pancreatic isles in acrylate-based hydrogels but we couldn't actually isolate cells from the immune system: antigens were released from the cells and that triggered a host response which killed the cells. However, that failure, lead us to a different polyacrylate that caused blood vessels to grow without growth factors. Now we use that material as an injectable gel to vascularize the subcutaneous space to permit pancreatic islet engraftment and restoration of normoglycemia – a good example of a successful failure.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"382 ","pages":"Article 113715"},"PeriodicalIF":10.5,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143798351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A ROS-responsive nanoprodrug-engineered phage biotherapy for precision treatment of multidrug-resistant gram-negative bacterial pneumonia.","authors":"Lanlan Dong,Baohua Zhao,Yifei Lu,Lanlan Li,Can Huang,Xuan Zhou,Tingting You,Wei Qian,Jianxiang Zhang,Gaoxing Luo","doi":"10.1016/j.jconrel.2025.113708","DOIUrl":"https://doi.org/10.1016/j.jconrel.2025.113708","url":null,"abstract":"Multidrug-resistant Gram-negative bacteria (MDR-GNB) pose a significant threat to global healthcare, causing severe morbidity and mortality rates in pneumonia cases. Despite the effectiveness of polymyxins, their clinical use is limited by toxicity and emerging bacterial resistance. Here, we describe a precisely targeting, biohybrid therapeutic platform that combines a polymyxin B-based prodrug nanosystem with an engineered phage. This biohybrid system enables the accumulation of polymyxin B at pathogens and its release in a reactive oxygen species (ROS)-triggered manner at inflamed sites. In vitro and in vivo studies demonstrate that this system shows robust lung distribution and tissue retention, effectively eliminating pathogens, reducing oxidative damage, and alleviating inflammation in a model of bacterial pneumonia. Our findings highlight the potential of this phage-prodrug biohybrid nanoplatform for targeted antibiotic delivery, offering a therapeutic paradigm against infectious diseases caused by MDR-GNB.","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"129 1","pages":"113708"},"PeriodicalIF":10.8,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143819321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}